To Evaluate Whether a Repeat Injection of Ranibizumab at 6 Weeks can Reduce the Rate of Disease Reactivation in Aggressive Retinopathy of Prematurity (AROP)
Not Applicable
- Conditions
- Health Condition 1: - Health Condition 2: H351- Retinopathy of prematurity
- Registration Number
- CTRI/2022/07/044475
- Lead Sponsor
- Janani Shishu Suraksha Karyakram
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Gestational age < 34 weeks (or higher with risk factors for ROP)
2. Birth weight < 2000 gram (or higher with risk factors for ROP)
3. Bilateral Zone 1 or Zone 2 Posterior AROP
4. No previous treatment
5. Clear media suitable for documentation and treatment
6. Pediatrician assesses the neonate to be fit enough for the procedure
Exclusion Criteria
1. Reactivation before 6 weeks after first dose of Ranibizumab
2. Parents unwilling for consent
3. Parents not willing for regular and complete follow up
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method